How Intract Is Helping Shape Microbiome-Based Therapies

 
• By Anju Ghangurde

Bill Lindsay, CEO of University College London spin-out Intract Pharma, tells Scrip in an interview how the firm’s novel technologies are expected to play a key role in the effective delivery of microbiome-based therapies.

Microbes
INTRACT EXPECTS ITS TECHNOLOGIES TO HELP OPTIMIZE DRUG DELIVERY

More from Business

More from Scrip